Cargando…

Single venom-based immunotherapy effectively protects patients with double positive tests to honey bee and Vespula venom

BACKGROUND: Referring to individuals with reactivity to honey bee and Vespula venom in diagnostic tests, the umbrella terms “double sensitization” or “double positivity” cover patients with true clinical double allergy and those allergic to a single venom with asymptomatic sensitization to the other...

Descripción completa

Detalles Bibliográficos
Autores principales: Stoevesandt, Johanna, Hofmann, Bernd, Hain, Johannes, Kerstan, Andreas, Trautmann, Axel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3846485/
https://www.ncbi.nlm.nih.gov/pubmed/24004607
http://dx.doi.org/10.1186/1710-1492-9-33
_version_ 1782293435616591872
author Stoevesandt, Johanna
Hofmann, Bernd
Hain, Johannes
Kerstan, Andreas
Trautmann, Axel
author_facet Stoevesandt, Johanna
Hofmann, Bernd
Hain, Johannes
Kerstan, Andreas
Trautmann, Axel
author_sort Stoevesandt, Johanna
collection PubMed
description BACKGROUND: Referring to individuals with reactivity to honey bee and Vespula venom in diagnostic tests, the umbrella terms “double sensitization” or “double positivity” cover patients with true clinical double allergy and those allergic to a single venom with asymptomatic sensitization to the other. There is no international consensus on whether immunotherapy regimens should generally include both venoms in double sensitized patients. OBJECTIVE: We investigated the long-term outcome of single venom-based immunotherapy with regard to potential risk factors for treatment failure and specifically compared the risk of relapse in mono sensitized and double sensitized patients. METHODS: Re-sting data were obtained from 635 patients who had completed at least 3 years of immunotherapy between 1988 and 2008. The adequate venom for immunotherapy was selected using an algorithm based on clinical details and the results of diagnostic tests. RESULTS: Of 635 patients, 351 (55.3%) were double sensitized to both venoms. The overall re-exposure rate to Hymenoptera stings during and after immunotherapy was 62.4%; the relapse rate was 7.1% (6.0% in mono sensitized, 7.8% in double sensitized patients). Recurring anaphylaxis was statistically less severe than the index sting reaction (P = 0.004). Double sensitization was not significantly related to relapsing anaphylaxis (P = 0.56), but there was a tendency towards an increased risk of relapse in a subgroup of patients with equal reactivity to both venoms in diagnostic tests (P = 0.15). CONCLUSIONS: Single venom-based immunotherapy over 3 to 5 years effectively and long-lastingly protects the vast majority of both mono sensitized and double sensitized Hymenoptera venom allergic patients. Double venom immunotherapy is indicated in clinically double allergic patients reporting systemic reactions to stings of both Hymenoptera and in those with equal reactivity to both venoms in diagnostic tests who have not reliably identified the culprit stinging insect.
format Online
Article
Text
id pubmed-3846485
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-38464852013-12-03 Single venom-based immunotherapy effectively protects patients with double positive tests to honey bee and Vespula venom Stoevesandt, Johanna Hofmann, Bernd Hain, Johannes Kerstan, Andreas Trautmann, Axel Allergy Asthma Clin Immunol Research BACKGROUND: Referring to individuals with reactivity to honey bee and Vespula venom in diagnostic tests, the umbrella terms “double sensitization” or “double positivity” cover patients with true clinical double allergy and those allergic to a single venom with asymptomatic sensitization to the other. There is no international consensus on whether immunotherapy regimens should generally include both venoms in double sensitized patients. OBJECTIVE: We investigated the long-term outcome of single venom-based immunotherapy with regard to potential risk factors for treatment failure and specifically compared the risk of relapse in mono sensitized and double sensitized patients. METHODS: Re-sting data were obtained from 635 patients who had completed at least 3 years of immunotherapy between 1988 and 2008. The adequate venom for immunotherapy was selected using an algorithm based on clinical details and the results of diagnostic tests. RESULTS: Of 635 patients, 351 (55.3%) were double sensitized to both venoms. The overall re-exposure rate to Hymenoptera stings during and after immunotherapy was 62.4%; the relapse rate was 7.1% (6.0% in mono sensitized, 7.8% in double sensitized patients). Recurring anaphylaxis was statistically less severe than the index sting reaction (P = 0.004). Double sensitization was not significantly related to relapsing anaphylaxis (P = 0.56), but there was a tendency towards an increased risk of relapse in a subgroup of patients with equal reactivity to both venoms in diagnostic tests (P = 0.15). CONCLUSIONS: Single venom-based immunotherapy over 3 to 5 years effectively and long-lastingly protects the vast majority of both mono sensitized and double sensitized Hymenoptera venom allergic patients. Double venom immunotherapy is indicated in clinically double allergic patients reporting systemic reactions to stings of both Hymenoptera and in those with equal reactivity to both venoms in diagnostic tests who have not reliably identified the culprit stinging insect. BioMed Central 2013-09-02 /pmc/articles/PMC3846485/ /pubmed/24004607 http://dx.doi.org/10.1186/1710-1492-9-33 Text en Copyright © 2013 Stoevesandt et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Stoevesandt, Johanna
Hofmann, Bernd
Hain, Johannes
Kerstan, Andreas
Trautmann, Axel
Single venom-based immunotherapy effectively protects patients with double positive tests to honey bee and Vespula venom
title Single venom-based immunotherapy effectively protects patients with double positive tests to honey bee and Vespula venom
title_full Single venom-based immunotherapy effectively protects patients with double positive tests to honey bee and Vespula venom
title_fullStr Single venom-based immunotherapy effectively protects patients with double positive tests to honey bee and Vespula venom
title_full_unstemmed Single venom-based immunotherapy effectively protects patients with double positive tests to honey bee and Vespula venom
title_short Single venom-based immunotherapy effectively protects patients with double positive tests to honey bee and Vespula venom
title_sort single venom-based immunotherapy effectively protects patients with double positive tests to honey bee and vespula venom
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3846485/
https://www.ncbi.nlm.nih.gov/pubmed/24004607
http://dx.doi.org/10.1186/1710-1492-9-33
work_keys_str_mv AT stoevesandtjohanna singlevenombasedimmunotherapyeffectivelyprotectspatientswithdoublepositiveteststohoneybeeandvespulavenom
AT hofmannbernd singlevenombasedimmunotherapyeffectivelyprotectspatientswithdoublepositiveteststohoneybeeandvespulavenom
AT hainjohannes singlevenombasedimmunotherapyeffectivelyprotectspatientswithdoublepositiveteststohoneybeeandvespulavenom
AT kerstanandreas singlevenombasedimmunotherapyeffectivelyprotectspatientswithdoublepositiveteststohoneybeeandvespulavenom
AT trautmannaxel singlevenombasedimmunotherapyeffectivelyprotectspatientswithdoublepositiveteststohoneybeeandvespulavenom